Updated:
Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company developing IV tramadol for acute and chronic pain. Publicly traded under ATXI, based in Florida.
Avenue Therapeutics
Avenue Therapeutics was incorporated in 2015 to develop and commercialize IV tramadol for the US market. The company is led by a management team with backgrounds in pharmaceutical development, though individual principals have not been publicly listed as family office operators. The firm focuses on a single pipeline asset: IV tramadol, a centrally acting analgesic, which had completed Phase 3 clinical trials for acute pain. Avenue Therapeutics has also explored additional pain management indications. The company operates as a publicly traded entity, with shares on the Nasdaq, allowing retail and institutional investors to participate. Avenue Therapeutics is headquartered in Florida, with no additional offices disclosed. The company has not publicly disclosed the number of employees or assets under management, and its structure as a public corporation rather than a traditional family office limits direct comparability. No recent operational events have been reported in the last 24 months that inform current posture. The firm's distinct structure as a publicly traded biotech developer, with a single focus on IV tramadol, sets it apart from diversified family offices. This narrow pipeline creates a high-risk, high-reward profile dependent on regulatory approval and market adoption.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Avenue Therapeutics?
Avenue Therapeutics is a publicly traded company, not a family office, so investment decisions are directed by its board of directors and management team. The company has not disclosed any family office affiliation or principals operating as family office managers.
How does Avenue Therapeutics source deal flow?
Avenue Therapeutics is a development-stage biotech company, not an investment firm. Its pipeline was internally developed through pharmaceutical research, and the company does not engage in typical investment deal flow or direct investments in other entities.
Is Avenue Therapeutics structured as a single family office or does it operate more like a venture firm?
Avenue Therapeutics is structured as a publicly traded corporation (Nasdaq: ATXI), not as a family office or venture firm. It operates as a specialty pharmaceutical company focused on a single drug candidate.
Does Avenue Therapeutics participate in fund commitments or only direct deals?
Avenue Therapeutics does not participate in fund commitments or direct investments in other companies. Its financial operations are limited to funding its own clinical trials and development activities through equity offerings and partnerships.
What investment stages does Avenue Therapeutics typically target?
Avenue Therapeutics does not target investment stages for external capital deployment. It is itself a development-stage company advancing its IV tramadol asset through Phase 3 clinical trials toward potential FDA approval.
Which sectors does Avenue Therapeutics explicitly avoid?
Avenue Therapeutics focuses exclusively on pharmaceutical development for pain management, specifically its IV tramadol formulation. The company has not expressed explicit sector exclusions but operates solely within the biotech/pharma space.
How is Avenue Therapeutics related to any parent or related entity?
Avenue Therapeutics is a standalone publicly traded company (ATXI). There is no public information linking it to a family office, conglomerate, or major pharmaceutical parent.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: